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ABSTRACT
Objectives: (1) To develop methods for conducting
cluster randomised trials of text messaging
interventions utilising routine electronic health records
at low cost; (2) to assess the effectiveness of text
messaging influenza vaccine reminders in increasing
vaccine uptake in patients with chronic conditions.
Design: Cluster randomised trial with general
practices as clusters.
Setting: English primary care.
Participants: 156 general practices, who used text
messaging software, who had not previously used text
message influenza vaccination reminders. Eligible
patients were aged 18–64 in ‘at-risk’ groups.
Interventions: Practices were randomly allocated to
either an intervention or standard care arm in the 2013
influenza season (September to December). Practices in
the intervention arm were asked to send a text message
influenza vaccination reminder to their at-risk patients
under 65. Practices in the standard care arm were asked
to continue their influenza campaign as planned.
Blinding: Practices were not blinded. Analysis was
performed blinded to practice allocation.
Main outcome measures: Practice-level influenza
vaccine uptake among at-risk patients aged
18–64 years.
Results: 77 practices were randomised to the
intervention group (76 analysed, n at-risk
patients=51 121), 79 to the standard care group (79
analysed, n at-risk patients=51 136). The text message
increased absolute vaccine uptake by 2.62% (95% CI
−0.09% to 5.33%), p=0.058, though this could have
been due to chance. Within intervention clusters, a
median 21.0% (IQR 10.2% to 47.0%) of eligible
patients were sent a text message. The number needed
to treat was 7.0 (95% CI −0.29 to 14.3).
Conclusions: Patient follow-up using routine
electronic health records is a low cost method of
conducting cluster randomised trials. Text messaging
reminders are likely to result in modest improvements
in influenza vaccine uptake, but levels of patients being
texted need to markedly increase if text messaging
reminders are to have much effect.
Trial registration number: ISRCTN48840025.
INTRODUCTION
Annual seasonal inﬂuenza vaccination is
offered to certain patient groups in the UK,
including patients aged 65 years and older,
and those who are aged under 65 years with
one or more chronic conditions (the ‘at-risk’
under 65s). The UK government sets targets
for vaccine uptake in these groups; in the
2013/2014 inﬂuenza season the target was
75%.1 While uptake in the over 65s reaches
this target in many practices, barriers to vac-
cination result in unmet targets for the
at-risk under 65s (uptake in 2012/2013 was
49.6%).2 These barriers include failure of
healthcare workers to recommend vaccin-
ation, low awareness of eligibility for vaccin-
ation, perceptions about severity of
inﬂuenza, and personal beliefs about vaccine
effectiveness, pain and side effects.3–5 In the
face of these barriers, strategies to improve
vaccine uptake are required.
Vaccination reminders by letter, postcard
and telephone have shown to be effective,6 7
but these interventions become costly when
Strengths and limitations of this study
▪ Text messaging is already commonly used in
general practice to remind patients about receiv-
ing their influenza vaccine, but this study is the
first to estimate the effectiveness of this
intervention.
▪ This cluster randomised trial in English primary
care recruited and randomised 156 general prac-
tices, including over 100 000 at-risk patients.
▪ The proportion of patients whose mobile tele-
phone numbers are recorded by their general
practice is low, limiting the power of our study
to detect an effect.
▪ Using routinely recorded electronic health
records to ascertain outcome data was a novel,
low-cost method of trial data collection.
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there are large numbers of at-risk patients. Text messa-
ging is a useful tool because it is cheap, fast and per-
sonal, and because mobile phone ownership in the UK
is widespread (94% of adults own a mobile phone).8
Consequently, text messaging has been increasingly used
in the National Health Service to contact patients for
appointment reminders and other health-related issues.
In the 2010–2011 inﬂuenza season, text messages were
used in roughly a third of practices for inﬂuenza vaccin-
ation reminders9 but there is no evidence that this strat-
egy increases uptake in primary care.
An emerging trial methodology utilises routinely col-
lected electronic health record sources to ascertain
outcome data, at far lower cost than traditional
methods of data collection.10 The feasibility of this
approach in primary care practices requires further
examination. Therefore we performed a cluster rando-
mised trial in English primary care, embedded within
routine electronic health records, to determine the
effectiveness of text message inﬂuenza vaccination
reminders in increasing inﬂuenza vaccination uptake
among the at-risk under 65s. Randomising individuals
within practices would have been logistically complex
and so a cluster design was chosen to reduce the
burden to practices of participating in our trial. The
aims of the study were (1) to develop the methods for
conducting cluster randomised trials of text messaging
interventions, and to evaluate feasibility of recruitment,
identiﬁcation of eligible practices and patients, and to
follow-up through routine electronic health records at
very low cost; and (2) to implement a cluster rando-
mised trial to test the effectiveness of using a text mes-
saging inﬂuenza vaccine reminder in achieving an
increase in practice-level inﬂuenza vaccine uptake in
patients aged 18–64 years with chronic conditions, com-
pared to standard care.
METHODS
Further details of our methods have been described pre-
viously in our published protocol,11 and the formal
study protocol is available in online supplementary
appendix 1.
Trial design
This was a two arm, pragmatic, cluster randomised trial,
with general practices as clusters allocated in a 1:1 ratio
to each arm.
General practice and patient eligibility
The study took place in the 2013/2014 inﬂuenza season
(vaccinations September–December) among English
primary care practices in three settings: (1) the Clinical
Practice Research Datalink (CPRD),12 a primary care
database based on Vision software and covering 8% of
the UK population; (2) TPP SystmOne software13 users;
(3) iPLATO text messaging software users in London14
(initially only practices in Islington and Barnet were
targeted, and this was later extended to all London bor-
oughs to achieve the required sample size).
Practices were recruited between July 2013 and
October 2013. Practices were eligible if they already used
text messaging software and did not use text messaging
to contact patients about inﬂuenza vaccine in the 2012/
2013 season. Eligibility of CPRD practices was deter-
mined based on the routinely recorded data and only
practices meeting the criteria were invited. All users of
iPLATO across London boroughs, and all practices using
TPP SystmOne software were invited to the trial and eli-
gibility was determined at the next stage.
Within participating practices, eligible patients were
those aged 18–64 years in at-risk groups due to chronic
conditions at the start of the inﬂuenza vaccination
season. This comprises patients who are under 65 with
chronic heart disease, chronic neurological disease, dia-
betes, chronic kidney disease, chronic liver disease,
chronic respiratory disease and immunosuppression, as
set out by the Chief Medical Ofﬁcer.15 Pregnant women
and carers, who are also eligible to get the vaccine, were
not targeted in our study to avoid ethics concerns (to
avoid contacting patients by text message whose circum-
stances are time dependent and may have changed
without being updated in the medical record). Practices
are able to identify these individuals as part of routine
care, as these patients are targeted for seasonal inﬂu-
enza vaccination. Patients were excluded from the study
if they transferred out of the practice or died before the
end of data collection (31 December 2013). Consent
was gained from the general practitioner at each general
practice, before randomisation had taken place. Patients
did not provide consent to be part of this trial. The trial
co-ordinator enrolled general practices and informed
the practices of their allocation.
Interventions
Practices were allocated to either a standard care arm or
an intervention arm. In the standard care arm, practices
were asked to continue with their seasonal inﬂuenza vac-
cination campaign as planned, typically using measures
such as posters in the practice and letters to patients. In
addition to their planned campaign, practices in the
intervention arm were asked to send a text message
inﬂuenza vaccination reminder using their in-practice
text messaging software, to patients aged 18–64 years in
at-risk groups. This required practices to perform two
steps: (1) identify eligible patients: most clinical software
systems have algorithms to identify eligible patients and
practices were encouraged to use these; (2) send a tai-
lored text message to these patients using software
embedded in the electronic health record.
The recommended text message content was “Hello
PATIENT NAME, to reduce your risk of serious health
problems from ﬂu, we recommend vaccination. Call
PRACTICE PHONE NUMBER to book. PRACTICE
NAME.” The message content was designed by behav-
ioural specialists and detail is given in the study
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protocol.11 Step by step instructions were provided (see
online supplementary appendix 2) but no formal train-
ing was given to practices as they were included in the
trial based on their experience in using text messaging
for other purposes (eg, appointment reminders).
Practices were instructed to send one text message to
their patients at the start of their seasonal inﬂuenza
campaign, but were free to send additional messages
later in the season if they chose to. Details of the inter-
vention delivery, including which member of staff sent
the text message, the time of day the messages were
sent, and whether messages were sent in bulk or indi-
vidually were left to the discretion of the practice
(though guidance was provided in the step by step
instructions).
Randomisation, allocation concealment and blinding
After enrolment to the trial, practices were randomly
allocated (1:1) to the standard care arm or the interven-
tion (inﬂuenza text messaging reminder) arm.
Randomisation was performed within strata deﬁned by
the clinical software system or text messaging software
used by each general practice (TPP SystmOne, CPRD,
iPLATO), and was additionally stratiﬁed by region (for
CPRD practices) and borough (for London-based prac-
tices). Block randomisation, using block sizes of 2, 4 and
6, was performed. The allocation sequence was gener-
ated by an independent statistician who was blind to
practice name. The trial co-ordinator, who enrolled the
practices and informed them of their allocation, was
unaware of the allocation until a complete block had
been randomised. It was not possible to blind practices
to their allocation but data management and analysis
were performed blind to allocation.
Outcomes
The primary outcome, measured at the cluster level (GP
practice), was inﬂuenza vaccination uptake among
patients aged 18–64 years in the seven prespeciﬁed risk
groups during the period between 1 September and 31
December 2013. This time period would have captured
the majority of inﬂuenza vaccinations.
Secondary outcomes were (1) the proportion of eli-
gible patients sent a text message, and (2) outcomes
used to establish the feasibility of our methods, includ-
ing the rate of recruitment, adherence to the text messa-
ging protocol, adverse events and problems with
message delivery, availability of electronic health record
data, and the time and cost required to gather data.
Data collection
Data on vaccination uptake, overall and by clinical risk
group, were obtained through extraction of routinely
collected data. Additional consent from GPs was
required for further demographic patient-level data
(age and sex) and so were only available for a subset. In
practices that contribute data to the CPRD or use TPP
SystmOne software, relevant patient-level data were
extracted from the database using prespeciﬁed Read
codes (the standard clinical terminology system used in
general practice in the UK). Within London practices
using iPLATO software, data were extracted by the clin-
ical software supplier of the practice or the practices
themselves. Data extracted included patient registration
details, age, sex, death date, clinical risk group, vaccin-
ation status and inﬂuenza vaccine invites. Codes indicat-
ing risk groups and vaccinations were identiﬁed using
PRIMIS Plus Read code lists, available online.16 In one
of the three settings, where text messaging was systemat-
ically recorded in the practice electronic health record,
adherence to the intervention was assessed by study
investigators. It was not possible to measure adherence
to the exact wording of the text message. All data were
stripped of personal identiﬁers before being supplied to
the study team. Where patient-level data were not avail-
able, practice-level data were supplied by Immform, the
UK’s surveillance system for inﬂuenza vaccine uptake.17
Sample size
To achieve 90% power with a 5% signiﬁcance level,
assuming an intracluster correlation of 0.024, 100 prac-
tices were required to identify a 7.5% relative increase in
vaccine uptake from 54% to 58%.18 To account for dif-
ferences in the number of eligible patients per practice
and dilution of the intervention effect through potential
contamination between arms, we chose to recruit and
randomise 150 practices to the study.11
Statistical methods
The primary analysis was by intent to treat, comparing
the cluster-speciﬁc proportions of vaccine uptake
between randomised arms using a two-sided t test, with
cluster proportions weighted to account for differing
numbers of at-risk patients across practices. Minimum-
variance weights were used,19 which weight cluster i by
ni=ð1þ ICCðni  1ÞÞ where ICC is the intracluster correl-
ation coefﬁcient and ni is the number of at-risk patients
in that cluster.
Sensitivity and subgroup analyses
We conducted a number of secondary analyses to
account for contamination between the randomised
arms. First, we used an instrumental variables approach
to ﬁt a structural mean model, using the minimum-
variance weights from the primary analysis, to estimate
the intervention effect under hypothetical full adher-
ence,20 that is, assuming all eligible patients in the active
arm received an inﬂuenza text message, and no eligible
patients in the other arm received a text message. We
additionally performed a per-protocol analysis which
restricted analysis to the patients in each practice who
actually received their allocated intervention. These ana-
lyses were restricted to practices for which data were
available regarding text messaging.
In a non-randomised preplanned comparison, we
explored whether the intervention effect differed by
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time of day the text message was sent by using a multi-
level logistic regression model including a random main
effect for practice ﬁtted to patient-level data. These ana-
lyses were also restricted to practices for which data were
available regarding text messaging.
A post hoc exploratory analysis was conducted using
similar multilevel logistic regression models to assess the
intervention effect within seven predeﬁned at-risk
patient subgroups.
To assess whether participation in the trial changed
vaccine uptake (Hawthorne effect), we compared prac-
tices taking part in the trial to those outside the trial
using the ResearchOne primary care database (a
research database holding over 400 TPP SystmOne
practices). T tests were used to compare the at-risk popu-
lation size and vaccine uptake of standard care practices
taking part in the trial to practices outside the trial. Data
were analysed using Stata V.14.1.
Missing data
Receipt of in-practice inﬂuenza vaccine was automatic-
ally recorded in the clinical system from which we
extracted the data, so there was no missing outcome
data. However, if patients received their inﬂuenza
vaccine outside the practice, this would not have been
recorded unless the patient informed their GP. Patients
transferring out of the practice or dying during the
study period were not included in the denominator.
Adherence to the intervention could not be measured
for all practices because speciﬁc vaccine reminder text
messages were systematically recorded for practices using
only TPP SystmOne clinical software.
Substudy
A substudy was conducted among two intervention prac-
tices, whose administrative staff sent a short question-
naire (four questions) to patients who had received the
text message. Questionnaires were sent after the data
collection phase for the trial was complete (December
2013). Patients were asked to return anonymised
responses directly to the study team by mail (postage
pre-paid) via a self-completion questionnaire (free of
any patient or practice identiﬁers) about their memory
of having received the text message, any objections to
the message, and whether it encouraged them to receive
the vaccine (Questionnaire in online supplementary
appendix 3).
Practice questionnaire
A questionnaire was sent to all practices in the interven-
tion group to identify comments and concerns from
practice staff regarding use of the text message (see
online supplementary appendix 4). The questionnaire
was sent electronically to the staff member who had
been the named contact for the trial, with practice staff
members able to complete online, and was sent in early
December, when practices were nearing the end of the
ﬂu vaccination season.
This trial was approved by Surrey Borders Ethics
Committee (13/LO/0872).
RESULTS
Our invitation to the trial was sent to over 2600 English
practices through the Primary Care Research Network,
TPP SystmOne practices, the CPRD and users of iPLATO
text messaging software. 376 expressed an interest in the
trial and 156 (41%) were eligible and provided consent
(ﬁgure 1). One hundred and ﬁfty-six practices partici-
pated in the study. Seventy-seven were allocated to the
intervention group and 79 to standard care (ﬁgure 1).
Practices were followed up for text messaging and inﬂu-
enza vaccine uptake between 1 September 2013 and 31
December 2013. Data for the primary outcome were
available in 155 of 156 practices. One intervention group
practice was lost to follow-up due to practice closure.
Additional demographic patient-level data, including age
and sex, were available in 144/156 practices (92%, 73/
79 standard care, 71/77 intervention). Overall, the ﬁnal
trial analysis included 102 257 at-risk patients aged 18–
64 years (table 1).
Primary outcome
In the standard care arm of the trial, mean vaccine
uptake across practices was 50.7% and in the interven-
tion arm was 52.4%. A minimum variance weighted t
test showed that there was an absolute 2.62% (95% CI
−0.09% to 5.33%) increase in practice-level vaccine
uptake among at-risk patients aged 18–64 years (two-
sided p value=0.058) in the text messaging intervention
group, compared to standard care (table 2, observed
ICC=0.029). This corresponds to a relative increase of
5.17%. In a sensitivity analysis, further adjustment for
clinical software system showed a similar absolute
increase in vaccine uptake of 2.66% (95% CI −0.03% to
5.34%, p=0.052). Based on this analysis, the number
needed to text (NNT) to achieve one additional inﬂu-
enza vaccination is 38.2 (95% CI −1.01 to 77.4).
Efficacy and per protocol analyses
Only TPP SystmOne practices recorded text messaging
systematically in a way that could be extracted from the
electronic health record. Among these practices (58
intervention, 58 standard care), in the intervention arm,
6 of 58 practices (10%) did not send any text message
to at-risk patients. In the standard care arm, 21 of 58
practices (36%) sent a vaccine reminder text message to
at least one patient. Among intervention practices, the
majority of messages were sent in September/October
(96%), with 4% sent in November/December. Among
the intervention practices, the median proportion of
patients sent a text message was 21.0% (IQR 10.2% to
47.0%), representing 156 messages per practice (IQR 65
to 287) (it was not possible to measure the proportion
of patients whose phone number was held by the prac-
tice) (table 3). In the standard care arm, the median
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proportion was 0% (IQR 0–6.3%), corresponding to a
median of zero messages per practice (IQR 0–61).
Characteristics of patients who were sent a message are
described in table 4.
In secondary analyses among practices where text mes-
sages were systematically recorded (TPP SystmOne
n=116 practices), instrumental-variables-based efﬁcacy
analyses demonstrated that texting 100% of eligible
patients, compared with texting 0%, could achieve a
14.3% (95% CI −0.59% to 29.2%) increase in vaccine
uptake. Based on this analysis, the NNT=7.0 (95% CI
−0.29 to 14.3). A more modest aim of texting 50% of
patients could achieve a 7.2% (95% CI −0.30% to
14.6%) increase in vaccine uptake.
A per protocol analysis using the same minimum vari-
ance weighted t test, but excluding patients who did not
receive their allotted intervention, showed an absolute
increase in vaccine uptake of 9.40% (95% CI 4.68% to
14.1%) in the text messaging intervention group, com-
pared to standard care.
Subgroup analyses: among risk groups
Post hoc exploratory analysis using mixed models
demonstrated that, overall, the odds of vaccination
increased by 12% (OR=1.12, 95% CI 1.00 to 1.25) in the
text messaging arm of the trial compared to standard
care. Within the seven risk groups (chronic heart
disease, diabetes, chronic respiratory disease, liver
disease, chronic kidney disease, chronic neurological
disease, immunosuppression) there was little variation in
the ORs; text messaging appears to work better in
patients with chronic heart disease (OR=1.19, 95% CI
1.05 to 1.34, p for interaction comparing the OR for
text messaging between patients with and without
chronic heart disease=0.036), though less well in
patients with diabetes (OR=1.04, 95% CI 0.93 to 1.17, p
for interaction=0.011) (table 5).
Subgroup analyses: by age and sex
Post hoc exploratory analyses showed no differences in
the effect of the intervention by age group or sex.
Results are shown in table 5.
Timing of text message
In a post hoc non-randomised analysis, compared to
patients for whom no message was sent, those receiving
a text message at any time of day had increased odds of
being vaccinated. The estimated effect of sending mes-
sages in the morning appeared to be slightly lower than
for other times of day, and the effect in the evening
appeared to be slightly higher (morning, up to midday
OR=1.18 (1.10 to 1.26); early afternoon 12:00–15:30
OR=1.40 (1.32 to 1.50); late afternoon 15:30—18:00
OR=1.29 (1.18 to 1.42); evening 18:00 onwards OR=1.44
(1.09 to 1.89), p for interaction between times of
day=0.002) (see online supplementary table S1).
Hawthorne effect
Among practices in ResearchOne, we compared prac-
tices in the standard care arm of the trial (n=55) to
those outside the trial (n=281) in terms of inﬂuenza
vaccine uptake. This showed no difference in uptake
Figure 1 Consort flow diagram.
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(uptake in trial 50.0%, uptake outside trial 50.8%,
p=0.53), though practices taking part in the trial tended
to have slightly larger at-risk populations than those not
taking part (mean practice at-risk population in trial 705
compared to 574 outside the trial, p=0.02).
Secondary outcomes
Interest in the trial was higher than anticipated, but our
inclusion criteria prevented 76 (20%) of interested prac-
tices from taking part. Among all practices invited, the
proportion recruited was roughly 6%.
Table 1 Distribution of clusters and eligible patients in the standard care and intervention arms of the trial
Standard care Intervention
N clusters 79 76
Region (n clusters)
South East 4 3
London 18 16
East of England 17 16
South West 9 8
West Midlands 1 3
East Midlands 12 12
North East and North West 4 3
Yorkshire and the Humber 14 15
Clinical software or iPLATO user
CPRD 1 2
TPP SystmOne 61 59
iPLATO 10 10
N patients at-risk 51 136 51 121
Median (minimum, maximum) at-risk patients per cluster 583 (125, 1678) 637 (79, 3022)
Sex, n (%)*
Men 24 420 (51.2) 24 182 (51.2)
Women 23 285 (48.8) 23 005 (48.8)
Age group, n (%)*
18–34 8113 (17.0) 8216 (17.4)
35–50 16 197 (34.0) 15 797 (33.5)
51–64 23 395 (49.0) 23 174 (49.1)
Risk group, n (%)†
Chronic heart disease 8419 (16.5) 8291 (16.2)
Diabetes 12 999 (25.4) 13 370 (26.2)
Chronic respiratory disease 24 244 (47.4) 24 393 (47.7)
Chronic liver disease 1728 (3.4) 1605 (3.1)
Chronic kidney disease 3190 (6.2) 3045 (6.0)
Chronic neurological disease 5949 (11.6) 5853 (11.4)
Immunosuppression 3341 (6.5) 3766 (7.4)
*From patient-level data, based on 145 practices (N=94 892; 47 705 standard care, 47 187 intervention).
†Groups not exclusive.
CPRD, Clinical Practice Research Datalink.
Table 2 Number of practices, patients and estimates of effectiveness for the text message influenza vaccine reminder
Standard care Intervention
Practice-level summary
Number of practices 79 76
Per cent vaccinated in cluster—median (minimum, maximum) 50.6 (27.7 to 76.2) 53.4 (38.5 to 81.1)
Per cent vaccinated in cluster—mean (SD) 51.7% (8.8%) 54.3% (8.4%)
Patient-level summary
Total patients 51 136 51 121
Number vaccinated 25 939 (50.7%) 26 804 (52.4%)
Estimated difference in uptake percentage:
Primary analysis* 2.62 (95% CI −0.09 to 5.33), p=0.058
Sensitivity analysis, further adjusting for data source† 2.66 (95% CI: −0.03 to 5.34) p=0.052
*Minimum variance weighted cluster t test.
† Data sources: CPRD, TPP SystmOne, EMIS/Vision; used to stratify randomisation.
CPRD, Clinical Practice Research Datalink.
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Practices in the trial understood the randomisation
process, but there was some contamination between trial
arms (table 3).
The patient substudy and practice questionnaire
allowed us to monitor adverse events and harms to
patients. Of 77 intervention group practices, 72 (94%)
responded to the practice questionnaire. Three practices
(4.2%) reported difﬁculties in sending the text message;
one because of a failure of the text messaging software,
one because ineligible patients were accidentally
selected to receive the message, and one because only
small numbers of patients had consented to receive
messages.
Five practices (6.9%) reported complaints from
patients about the message (though numbers of
complaints were not recorded): due to ineligible
patients receiving messages (n practices=1), receipt of
>1 message (n=1); receipt of a reminder after making
an appointment (n=1), and two resulting from protocol
deviation (text message was missing the recipient’s name
or message contained incorrect clinic times). Sixty-two
practices (86.1%) reported that text messaging for inﬂu-
enza vaccine reminders was worthwhile. No unintended
effects were reported to the study team.
Eight hundred and twenty-ﬁve patients were invited to
complete the substudy questionnaire. One hundred
patients responded (response rate 12%). Three quarters
(75/100) recalled receiving the text message. Of those
that recalled the message, 4 (5.3%) objected to the
message with no reason given, but 48 (64.0%) reported
Table 3 Summary of adherence to randomised allocation in 116 TPP SystmOne subset of practices
Standard care Intervention
Practice-level summary
N practices 58 58
At least 1 influenza vaccine reminder text message sent—N practices (%) 21 (36.2) 52 (89.7)
Percentage of eligible patients texted—N practices (%)
None 37 (63.8) 6 (10.3)
1% to <10% 7 (12.1) 8 (13.8)
10% to <20% 4 (6.9) 14 (24.1)
20% to <50% 7 (12.1) 18 (31.0)
50% to <75% 2 (3.5) 10 (17.2)
75% to 100% 1 (1.7) 2 (3.5)
Percentage of eligible patients sent a message—median (IQR) 0 (0–6.3) 21.0 (10.2–47.0)
Number of messages sent—median (IQR) 0 (0–61) 155.5 (65–287)
Number of messages sent—mean (SD) 45.3 (84.9) 191.6 (164.2)
Patient-level summary
Number (%) of patients sent a message 2628 (6.5%) 11 113 (27.1%)
Table 4 Text messages sent to patients in the standard care and intervention arms of the trial, by clinical risk group and
demographic characteristics
Standard care Intervention
N in group
Sent text
message n (%) N in group
Sent text
message n (%)
N 43 143 2732 (6.3) 44 037 11 515 (26.1)
Clinical risk group*
Chronic heart disease 6651 436 (6.6) 6657 1698 (25.5)
Diabetes 2367 136 (5.7) 2387 630 (26.4)
Chronic respiratory disease 1251 66 (5.3) 1182 321 (27.2)
Chronic liver disease 4571 252 (5.5) 4583 1030 (22.5)
Chronic kidney disease 20 240 1187 (5.9) 20 703 5462 (26.4)
Chronic neurological disease 10 120 999 (9.9) 10 318 3807 (36.9)
Immunosuppression 2343 87 (3.7) 2341 490 (20.9)
Age group*
18–34 6823 426 (6.2) 7050 1948 (27.6)
35–50 13 809 958 (6.9) 13 598 4147 (30.5)
51–64 20 001 1244 (6.2) 22 425 5018 (24.6)
Sex*
Male 20 752 1464 (7.1) 21 012 5777 (27.5)
Female 19 881 1164 (5.9) 20 061 5336 (26.6)
*Available in patient-level data from TPP SystmOne users only (N=116 practices, 81 706 patients; 40 633 standard care, 41 073 intervention).
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being encouraged by the text message to make an
appointment for their vaccine.
A ﬁnal outcome was to evaluate the feasibility of ascer-
taining practice data regarding text message delivery
and inﬂuenza vaccine uptake. Changes were made to
the methods for ascertaining outcome data in response
to difﬁculties in acquiring outcome data via the planned
routes. One practice withdrew from the trial due to
closure during data collection. For the remaining 155
practices, access to data from existing primary care data-
bases (practices in CPRD and ResearchOne, the
primary care database of over 400 TPP SystmOne prac-
tices) was straightforward. These databases provided
data for 111 practices. However, ascertaining the data
was more expensive and logistically complex than
expected for iPLATO software users and among prac-
tices that did not consent to join the CPRD and
ResearchOne databases (N=44 practices; 21 intervention
group). For these practices, access to data was possible
directly through TPP SystmOne, and with some add-
itional costs data were accessed through clinical software
providers EMIS and Vision (see online supplementary
table S2). Through these routes (with full practice
consent), full patient-level data were available from 144
practices.
Data from 11 practices were available only at practice-
level, and after gaining practice consent, this was pro-
vided through Immform.17 This allowed assessment of
the primary outcome (vaccine uptake) among sub-
groups of risk but contained no information on text
messaging, age or sex. Additionally, in most data
sources, text messaging is not recorded systematically,
meaning that we were only able to perform efﬁcacy and
per-protocol analyses among practices using TPP
SystmOne software. The additional costs of data collec-
tion raised the cost of the trial substantially but the total
cost of the trial was less than £1 per patient.
A breakdown of costs is given in table 6.
DISCUSSION
Statement of principal findings
Embedding a trial within existing, routinely recorded
primary care electronic health records was a feasible,
efﬁcient and low-cost approach. Practices allocated to
the text messaging intervention arm had higher inﬂu-
enza vaccine uptake among at-risk patients aged 18–
64 years than practices allocated to standard care.
However, there was only weak evidence of an effect and
the increase may have been due to chance. In most
practices, adherence to the intervention was low and
messages were sent to an average of one-ﬁfth of eligible
patients. An efﬁcacy analysis indicated that if practices
sent a reminder text message to 50% of at-risk patients,
vaccine uptake could increase by an absolute propor-
tion of 7%, while texting 100% of patients could
achieve a 15% increase in uptake. This indicates that
the modest intervention effect observed may be partly
Table 5 Vaccination uptake and intervention effectiveness by subgroups of clinical risk group, age group and sex
Standard care Intervention
N in group Vaccinated n (%) N in group Vaccinated n (%) OR (95% CI)
N 51 136 25 939 (50.7) 51 121 26 804 (52.4) 1.11 (1.00 to 1.25)
Clinical risk group
Chronic heart disease 8419 4409 (52.4) 8291 4592 (55.4) 1.19 (1.05 to 1.34)
Diabetes 12 999 8968 (69.0) 13 370 9294 (69.5) 1.04 (0.93 to 1.17)
Chronic respiratory disease 24 244 11 767 (48.5) 24 393 12 180 (49.9) 1.12 (1.00 to 1.25)
Chronic liver disease 1728 730 (42.2) 1605 700 (43.6) 1.11 (0.94 to 1.33)
Chronic kidney disease 3190 1727 (54.1) 3045 1722 (56.6) 1.14 (0.98 to 1.32)
Chronic neurological disease 5949 2906 (48.8) 5853 2979 (50.9) 1.14 (1.00 to 1.30)
Immunosuppression 3341 1686 (50.5) 3766 2029 (53.9) 1.19 (1.03 to 1.37)
Age group*
18–34 8113 2574 (31.7) 8216 2755 (33.5) 1.16 (1.01 to 1.32)
35–50 16 197 7344 (45.3) 15 797 7382 (46.7) 1.11 (0.98 to 1.25)
51–64 23 395 14 255 (60.9) 23 174 14 423 (62.2) 1.10 (0.98 to 1.24)
Sex*
Male 24 420 11 876 (48.6) 24 182 12 208 (50.5) 1.12 (1.00 to 1.26)
Female 23 285 12 297 (52.8) 23 005 12 352 (53.7) 1.09 (0.97 to 1.23)
*Available in patient-level data only (N=145 practices, 101 159 patients; 50 659 standard care, 50 500 intervention).
Table 6 Breakdown of trial costs for TXT4FLUJAB
Cost in GBP (£)
Incentive payments for intervention
group
15 600.00
Invitation letters, postage, administration 3700.00
iPLATO software support 1200.00
Planned data costs 3500.00
Research coordination and analysis 50 000.00
Unplanned data costs 20 600.00
Substudy cost 2770.00
Trial sponsorship 1000.00
Total 98 370.00
8 Herrett E, et al. BMJ Open 2016;6:e010069. doi:10.1136/bmjopen-2015-010069
Open Access
attributable to low adherence. Participating practices
tended to have larger at-risk populations than practices
outside the trial. The standard care arm had the same
vaccine uptake as practices not in the trial, indicating
that our results are likely to be generalisable to all prac-
tices in England. Recent evidence has shown that text
messaging is effective in other contexts,21 22 and our
trial recruitment phase, questionnaire and substudy
indicated the popularity of text messaging among prac-
tices and patients. Our trial provided some evidence
that this intervention is likely to result in modest
improvements in inﬂuenza vaccine uptake among at-risk
groups aged 18–64 years.
Strengths
This study demonstrates the feasibility of embedding a
trial within routinely recorded primary care electronic
health records. Recruitment was feasible with the
support of the NIHR Primary Care Research Networks.
Our method was advantageous for two reasons: ﬁrst, it
minimised the burden of research for practices and
encouraged recruitment, and second, it reduced the
cost compared to trial-speciﬁc data collection. We have
established the feasibility of recruiting practices (beyond
initial expectations), randomising practices to a text mes-
saging intervention and ascertaining outcome data using
the electronic health record. Our intervention was
simple and easy for practices to implement and this was
reﬂected in the positive feedback that we received from
practices in the text messaging group. Very few patients
expressed annoyance at receiving the message, and
while there may have been a response bias in our sub-
study results, we believe that those who did not respond
are less likely to have concerns. One of the key measures
of feasibility was our ability to obtain outcome data from
practices and, unfortunately, concern over data sharing,
particularly in response to care.data,23 brought chal-
lenges to outcome ascertainment. We obtained patient-
level data for 144 of 156 practices and primary outcome
data for 155. In doing so we have identiﬁed that the
optimal method for trials attempting to use electronic
health record data is to use only practices with estab-
lished data extraction procedures. Our trial was a cost-
effective approach to reach a population of over 100 000
at-risk patients, costing less than £1 per patient. Further
cost-savings would have been possible by using only prac-
tices in established research databases.
Limitations
Adherence to the intervention
There was some contamination between the interven-
tion and standard care arms: roughly one-third of stand-
ard care practices chose to send a message and
one-tenth of intervention practices failed to send a
message. This reduced the power of our trial to identify
a difference between groups; ﬁnancial incentives to prac-
tices for adherence to the intervention may have been
beneﬁcial to reduce contamination. In intervention
group practices, an average of one-ﬁfth of patients were
sent a message. This was low because not all patients
have a mobile phone and many do not give their
numbers to their general practice, meaning that the
pool of eligible patients that could receive the interven-
tion was smaller than expected. One of the strengths of
the trial was that it was restricted to practices that
already used text messaging for other purposes, so the
proportion of the patient population with a mobile
phone number recorded would have been higher than
texting-naïve practices. However, it was not possible to
measure the proportion of patients for whom a valid
mobile phone number was held. A common issue for
practices wishing to use text messaging is consent. At the
time of the trial, there were no laws in place about
gaining consent from patients about text messaging.
The NHS has produced guidance for text messaging,24
though it does not differentiate between the two models
of consent available to practices: (1) an ‘implied
consent’ or ‘opt-out’ approach, in which the practice
assumes consent for those patients who have provided a
mobile telephone number; practices using the ‘implied
consent’ approach must have procedures in place to
ensure that they meet the NHS Conﬁdentiality Code of
Practice25; (2) an ‘explicit consent’ or ‘opt-in’ approach,
in which each patient must provide explicit consent to
receive text messages, even after they have supplied
their number. The decision about consent is therefore
not straightforward but the Medical Protection Society
now recommends that practices should not assume
consent and should ask for it explicitly.26 Therefore the
proportion of patients who can be sent text messages
may not increase at a fast pace.
No data were available on the proportion of patients
that received or read the text message. Our efﬁcacy ana-
lysis assuming intervention adherence of 100% showed
that sending text message vaccine reminders could
achieve an increase in vaccine uptake as high as 14%.
However, the response to a text message reminder
among patients who have not provided a mobile tele-
phone number to their general practice may not be the
same as those who have already given their number.
As practice staff members identiﬁed at-risk patients and
sent the text message using in-practice software, we were
unable to control adherence to the intervention. Though
we were unable to assess the wording of the text message
(as this is not routinely recorded by practices) several
practices reported modiﬁcation of the message to suit
vaccination clinic times. We believe that the disadvantages
of our approach to implementation are outweighed by
the advantages of the pragmatic design and cost-savings.
Comparison to other literature
This is the ﬁrst study to evaluate the use of text messa-
ging for vaccination reminders in English primary care.
In the USA, an individually randomised controlled trial
in a low-income population evaluated the use of text
messaging reminders sent to parents about their child’s
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inﬂuenza vaccinations. This study showed that text mes-
saging was responsible for a 9% relative increase in
vaccine uptake.27 Elsewhere, text messaging has proven
effective in reducing non-attendance for appointments
compared to no intervention,28 to aid smoking cessation
and to improve adherence to antiretroviral treatment.29
There is also good evidence that inﬂuenza vaccination
reminders (letters, postcards and phonecalls) are effect-
ive at improving uptake.7 However, when compared
against other reminder types, a systematic review showed
no beneﬁt of text messaging for appointment
attendance.28
Based on this evidence, we believe that text messages
are likely to have some effect on vaccination uptake, but
our ability to detect an effect was limited by non-
adherence and the following two factors: (1) the prac-
tices in our trial were instructed to carry out their
seasonal inﬂuenza vaccine strategy as planned, with the
intervention group additionally asked to send a text
message to their at-risk patients. If practices were already
devoting resources to their inﬂuenza campaigns (eg,
emails, letters, phone calls, face-to-face reminders), an
additional text message may not be expected to substan-
tially improve uptake. We were unable to assess the
effect of other reminder methods as they were not rou-
tinely or systematically recorded in the patient electronic
health record. (2) While our message addressed some
key barriers to vaccination among the at-risk groups (rec-
ommendation from general practitioner, severity of
inﬂuenza, patient’s susceptibility to inﬂuenza, prompt
for patients that may simply have forgotten),3–5 there
may be remaining barriers that a single text message is
unable to overcome, for example, our message would
have no effect on patients that are unable to attend
clinic times, patients who are concerned about vaccine
side effects, or patients who simply do not wish to be
vaccinated. These remaining barriers limit the potential
of text messaging to improve uptake. These factors may
have contributed to the modest intervention effect
observed in our study.
There has recently been a move towards more efﬁ-
cient randomised trial designs gathering follow-up data
at lower cost from existing data sets. For example: the
TASTE trial examined the effect of thrombus aspiration
before percutaneous coronary intervention (PCI), using
the existing Swedish Coronary Angiography and
Angioplasty Registry for follow-up data;30 the SAFE-PCI
trial compared the safety of radial or femoral access for
PCI using the existing National Cardiovascular Data
Registry CathPCI Registry (although this trial was aban-
doned for futility due to low event rates);31 32 while two
low cost pragmatic randomised trials in the UK used
routinely collected NHS primary care electronic health
records for outcome data, RETRO-PRO comparing ator-
vastatin against simvastatin,10 and eLung comparing
immediate or deferred antibiotics for mild to moderate
exacerbation of COPD.10 Our study, albeit a cluster ran-
domised trial, was by far the cheapest of any such
low-cost pragmatic trial published to date. An overview
of the costs in this trial is presented in table 6. Our trial
was restricted to practices that were existing users of text
messaging and for practices that have not used texting
before, there may be some set-up costs for text messa-
ging software. However, these costs do not apply for all
software systems and are often borne by the local
Clinical Commissioning Group, meaning that the inter-
vention remains cheap at the practice level.
Implications
Text messaging is a low-cost intervention, popular with
patients and quick for practice staff to implement. As
practices are incentivised to vaccinate clinical risk
groups as part of the Quality Outcomes Framework
(QOF) (those with COPD, coronary heart disease, cere-
brovascular disease and diabetes), and as part of the
NHS Enhanced Service,33 a low-cost intervention that
may help to increase uptake is likely to have wide
appeal. While our trial provides no deﬁnitive conclusion
about the effectiveness of text message inﬂuenza vaccine
reminders, it does show that most practices are only able
to send text messages to a minority of patients within
their practice. If text messaging is to replace invitation
letters, or be used as an additional strategy to improve
vaccine uptake, then levels of patients being texted
would need to markedly increase in order to have an
important effect. Use of text message technology is
increasing and we have provided some evidence for its
utility for increasing vaccine uptake among at-risk
groups under 65. We have also demonstrated that cluster
randomised trials using routinely collected electronic
health record data can be conducted at very low cost.
CONCLUSION
This trial demonstrated the feasibility of text messaging
interventions for cluster randomisation within English
general practice. Owing to the growth of technology and
mobile phone usage, we recommend further research to
evaluate whether repeated or personalised messages are
effective at increasing vaccination uptake in those aged
18–64 years at-risk, and strategies to increase the number
of eligible patients with mobile phone numbers
recorded. Given the low cost of this trial (<£1 per
patient), the novel trial methods used here could be
applied to a wide variety of questions relevant to the
National Health Service.
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